|本期目录/Table of Contents|

[1]刘年安,李新,唐海荣,等.瑞舒伐他汀联合曲美他嗪对冠心病合并慢性心力衰竭患者心功能及炎症反应的改善作用[J].医学研究与战创伤救治(原医学研究生学报),2019,21(02):156-159.[doi:10.3969/j.issn.1672-271X.2019.02.009]
　LIUNian-an,LIXin,TANGHai-rong,et al.Effect of rosuvastatin combined with trimetazidine on improvement of heart function and inflammation in patients with coronary heart disease and chronic heart failure[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(02):156-159.[doi:10.3969/j.issn.1672-271X.2019.02.009]
点击复制

瑞舒伐他汀联合曲美他嗪对冠心病合并慢性心力衰竭患者心功能及炎症反应的改善作用()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第21卷
期数:
2019年02期
页码:
156-159
栏目:
临床研究
出版日期:
2019-03-20

文章信息/Info

Title:
Effect of rosuvastatin combined with trimetazidine on improvement of heart function and inflammation in patients with coronary heart disease and chronic heart failure
作者:
刘年安; 李新; 唐海荣; 卢小媚
作者单位：210019 南京，南京明基医院心血管内科（刘年安、李 新、唐海荣、卢小媚）
Author(s):
LIU　Nian-an;  LI　Xin;  TANG　Hai-rong;  LU　Xiao-mei
（Department of Cardiovascular Medicine，Nanjing BenQ Medical Center，Nanjing 210019，Jiangsu，China）
关键词:
瑞舒伐他汀; 曲美他嗪; 冠心病; 心功能不全
Keywords:
rosuvastatin;  trimetazidine;  coronary heart disease;  ventricular dysfunction
分类号:
R541.4;R541.6
DOI:
10.3969/j.issn.1672-271X.2019.02.009
文献标志码:
A
摘要:
目的　观察瑞舒伐他汀联合曲美他嗪对冠心病合并慢性心力衰竭患者心功能及炎症反应的影响。 方法　回顾性分析南京明基医院2016年1月至2017年9月确诊为冠心病合并心力衰竭94例患者临床资料，按照治疗方案不同分为联合组（n=45）和对照组（n=49）。对照组在综合治疗基础上服用瑞舒伐他汀10 mg/次，1次/d，联合组患者此基础上联合服用曲美他嗪片20 ｍg/次，3次/d。治疗6个月后，根据美国纽约心脏学会（NYHA）心功能分级比较2组患者的治疗效果，多普勒超声检测治疗前后血液流变学指标，ELISA法检测血清炎症因子。 结果　联合组的有效率显著高于对照组（91.1% vs 75.5%，P<0.05）。治疗后2组左心室射血分数（LVEF）、左室短轴缩短率（LVFS)和二尖瓣最大流速与心房收缩期血流最大流速比值（E/A）均显著改善（P<0.05），联合组改善效果显著优于对照组（P<0.05）；治疗后2组血清超敏C蛋白（hs-CRP）、肿瘤坏死因子（TNF-α）和白介素-10（IL-10）均显著下降（P<0.05），联合组改善效果显著优于对照组（P<0.05）。 结论　瑞舒伐他汀联合曲美他嗪可有效提升冠心病合并心力衰竭患者心功能，改善心脏血流流变学，并可降低患者体内炎症反应。
Abstract:
Objective　To observe the effect of rosuvastatin combined with trimetazidine on heart function and inflammatory reaction in patients with coronary heart disease and chronic heart failure.　Methods　Clinical data of 94 patients with coronary heart disease and chronic heart failure diagnosed in Nanjing BenQ Medical Center from January 2016 to September 2017 was analyzed retrospectively. According to different treatment options, patients were divided into combination group (n=45) and control group (n=49). The control group was given rosuvastatin on the basis of comprehensive treatment (10 mg/time，1 time/d). The combination group was given the combination of trimetazidine tablets (20 mg/time, 3 times/d). After 6 months of treatment, the therapeutic effects of the two groups were compared according to the New York Heart Association (NYHA) cardiac function classification, hemorheology indexes before and after treatment with Doppler ultrasound, and serum inflammatory factors detected by ELISA.　Results　The effective rate of the combination group was significantly higher than that in the control group (91.1% vs 75.5%, P<0.05). After the treatment, left ventricular ejection fraction (LVEF), left ventricular short axis shortening (LVFS) and mitral flow velocity ratio (E/A) were significantly improved (P<0.05). Moreover, the improvement effect of combination group was significantly better than that in the control group (P<0.05). After the treatment, serum hs-CRP, TNF-α and IL-10 were significantly decreased in two groups (P<0.05) and the improvement effect in the combination group was significantly better than that in the control group (P<0.05).　Conclusion　Rosuvastatin combined with trimetazidine can effectively improve heart function, improve cardiac rheology, and reduce inflammatory response in patients with coronary heart disease and heart failure.

参考文献/References:

[1] 马岩，黄建立，刘改祥，等.西药联合中药治疗冠心病型心力衰竭的疗效观察[J].中国全科医学，2016，19(S1):421-423.
[2] 崔腾斌.阿托伐他汀对冠心病性心力衰竭患者血浆hs-CRP水平及心功能的影响[J].山东医药，2014，54(8):42-44.
[3] Amber KI，Hadi NR，Muhammadbaqir B M，et al.Trimetazidine attenuates the acute inflammatory response induced by Novolimus eluting bioresorbable coronary scaffold implantation[J].Int J Cardiol，2016，220:514-519.
[4] 中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42(2):3-10.
[5] 张育，顾健，朱妍.内科学[M].北京：科学出版社，2016：84 -85.
[6] 胡丽华，程晓曙.他汀类药物的多效性在慢性心力衰竭中作用的研究进展[J].广东医学，2016，37(20):3130-3132.
[7] 马维军.中西医结合治疗冠心病的新进展[J].临床医学研究与实践，2016，1(19):196.
[8] 林晓明，陈生晓，钟春，等.不同剂量阿托伐他汀治疗冠心病慢性心力衰竭疗效分析[J].山东医药，2014，54(17):60-61.
[9] Hognestad A，Dickstein K，Myhre E，et al.Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure[J].Am J Cardiol，2004，93(5):603-606.
[10] Spencer FA，Allegrone J，Goldberg RJ.Association of statin therapy with outcomes of acute coronary syndromes:The GRACE study[J].Ann Intern Med，2004，13(8):857-866.
[11] 邵波，王炳银，陈润祥，等.曲美他嗪对冠心病慢性心力衰竭患者心功能及心率震荡的影响[J].中国康复理论与实践，2014，20(4):382-384.
[12] Di NP，Taccardi AA，Barsotti A.Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy[J].Heart，2005，91(2):161-165.
[13] 李堪董，赵圣吉，史丽.曲美他嗪联合美托洛尔治疗老年冠心病合并心力衰竭的临床研究[J].中国临床药理学杂志，2018,34 (5)：507-510.
[14] 郭峰，周乃珍.曲美他嗪片治疗冠心病心力衰竭的临床研究[J].中国临床药理学杂志，2017，33(15):1406-1408.
[15] Liang S，Aiqun M，Figtree G，et al.Combination therapy with coenzyme Q10 and trimetazidine in acute viral myocarditis patients[J].J Cardiovasc Pharmacol，2016，68(2):150-154.

相似文献/References:

[1]童成刚,崔云惠,于连荣,等.曲美他嗪治疗老年冠心病稳定性心绞痛的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2012,14(02):138.
　TONG Cheng-gang,CUI Yun-hui,YU Lian-rong,et al.The clinical observation of trimetazidine treatment of coronary heart disease with stable angina in aged patients[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(02):138.
[2]龚正华,黄建安.瑞舒伐他汀对COPD患者血清白介素8及生活质量的影响[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):57.[doi:10.3969/j.issn.1672-271X.2015.01.019]
　GONG Zheng-hua,HUANG Jian-an.The observation of rosuvastatin affect on IL-8 and the quality of life on COPD patients[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(02):57.[doi:10.3969/j.issn.1672-271X.2015.01.019]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2019-03-20